BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BioCentury | Mar 23, 2018
Clinical News

Immuron reports Phase II data for NASH candidate

...of patients who received high-dose IMM-124E achieved a ≥15% reduction in serum cytokeratin 18 (CK18; KRT18...
BioCentury | Feb 3, 2017
Clinical News

Oral DUR-928: Ph Ib data

...patients. Additionally, Durect said DUR-928 reduced full length and cleaved cytokeratin 18 ( CK18 ; KRT18...
BioCentury | May 16, 2016
Clinical News

Emricasan: Additional Phase II data

...inhibitor Indication: Treat liver cirrhosis Endpoint: Change in baseline cleaved cytokeratin 18 ( CK18 ; KRT18...
BioCentury | Jan 11, 2016
Clinical News

Emricasan: Phase II data

...86 patients with liver cirrhosis showed that twice-daily 25 mg oral emricasan significantly reduced cleaved CK18...
...reduced caspase-3 ( CASP3 ; CPP32 )/ caspase-7 ( CASP7 ; MCH3 ) (p<0.0001); full-length CK18...
...inhibitor Indication: Treat liver cirrhosis Endpoint: Change in baseline cleaved cytokeratin 18 ( CK18 ; KRT18...
BioCentury | Oct 5, 2015
Clinical News

Emricasan: Phase II data

...pressure in the portal vein, in patients with severe portal hypertension and of reducing cleaved CK18...
...mean baseline HPVG of 15.2 mmHg (p=0.26). In all 22 patients, emricasan significantly reduced cleaved CK18...
...patients with liver cirrhosis Endpoint: Change from baseline in cleaved cytokeratin 18 ( CK18 ; KRT18...
BioCentury | Sep 28, 2015
Analyst Picks & Changes

Finance

...He said emricasan has a unique mechanism of action that targets cleaved cytokeratin 18 (CK18; KRT18...
BioCentury | May 4, 2015
Clinical News

Emricasan: Additional Phase II data

...change in aspartate aminotransferase (AST) levels, cytokeratin 18 ( CK18 ; KRT18 ) and cleaved CK18...
BioCentury | Mar 30, 2015
Clinical News

Emricasan: Phase II data

...baseline to day 28 vs. placebo (39% vs. 14%, p<0.05). Additionally, emricasan significantly reduced cleaved CK18...
...day 28 vs. an increase of about 4% for placebo. Emricasan also significantly reduced full-length CK18...
...change in aspartate aminotransferase (AST) levels, cytokeratin 18 ( CK18 ; KRT18 ) and cleaved CK18...
BioCentury | Mar 27, 2015
Clinical News

Conatus' emricasan meets Phase II endpoint

...biomarkers that were elevated at baseline: caspase-cleaved cytokeratin 18 ( CK18 ; KRT18 ), full-length CK18...
Items per page:
1 - 10 of 18